Low-dose Nilotinib and Imatinib Combination in Chronic Myeloid Leukemia Patients, With Failure, Suboptimal Response or Treatment Intolerance

NCT01819389 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Leukemia, Myeloid, Chronic, BCR-ABL Positive

Interventions

DRUG: Imatinib and Nilotinib

Sponsor

Hospital Universitario Dr. Jose E. Gonzalez

Collaborators

[object Object]